Healthcare provider profile · identity verified

Andy Glee Goodner, MD

Family Practice · DECORAH, IA · NPI 1548214190

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	637	154
Levothyroxine Sodium	Levothyroxine Sodium	302	70
Amlodipine Besylate	Amlodipine Besylate	297	81
Metoprolol Tartrate	Metoprolol Tartrate	266	48
Lisinopril	Lisinopril	254	73
Losartan Potassium	Losartan Potassium	240	71
Metoprolol Succinate	Metoprolol Succinate	230	57
Furosemide	Furosemide	198	58
Rosuvastatin Calcium	Rosuvastatin Calcium	194	52
Pantoprazole Sodium	Pantoprazole Sodium	186	54
Gabapentin	Gabapentin	173	36
Jardiance	Empagliflozin	170	37
Tamsulosin Hcl	Tamsulosin Hcl	131	36
Metformin Hcl Er	Metformin Hcl	130	31
Omeprazole	Omeprazole	130	43
Eliquis	Apixaban	129	29
Tramadol Hcl	Tramadol Hcl	109	26
Hydrochlorothiazide	Hydrochlorothiazide	106	30
Alendronate Sodium	Alendronate Sodium	101	29
Allopurinol	Allopurinol	97	28
Ozempic	Semaglutide	76	16
Famotidine	Famotidine	73	19
Clopidogrel	Clopidogrel Bisulfate	72	11
Simvastatin	Simvastatin	68	21
Donepezil Hcl	Donepezil Hcl	67	12
Fluticasone Propionate	Fluticasone Propionate	66	19
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	64	16
Metformin Hcl	Metformin Hcl	63	18
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	62	18
Warfarin Sodium	Warfarin Sodium	62	18
Trulicity	Dulaglutide	61	suppressed
Xarelto	Rivaroxaban	61	16
Finasteride	Finasteride	60	15
Albuterol Sulfate Hfa	Albuterol Sulfate	55	25
Duloxetine Hcl	Duloxetine Hcl	55	13
Glipizide Er	Glipizide	54	13
Citalopram Hbr	Citalopram Hydrobromide	53	16
Jantoven	Warfarin Sodium	52	13
Carvedilol	Carvedilol	50	suppressed
Sertraline Hcl	Sertraline Hcl	50	14
Trazodone Hcl	Trazodone Hcl	48	14
Potassium Chloride	Potassium Chloride	47	19
Abrysvo	Rsv Vacc, Pref A And Pref B/Pf	44	44
Prednisone	Prednisone	44	30
Meloxicam	Meloxicam	43	14
Paroxetine Hcl	Paroxetine Hcl	43	suppressed
Escitalopram Oxalate	Escitalopram Oxalate	39	12
Oxycodone Hcl	Oxycodone Hcl	38	suppressed
Lorazepam	Lorazepam	37	12
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	36	15
Atenolol	Atenolol	34	suppressed
Spironolactone	Spironolactone	34	suppressed
Spiriva Respimat	Tiotropium Bromide	31	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	29	18
Carbidopa-Levodopa	Carbidopa/Levodopa	28	suppressed
Klor-Con M20	Potassium Chloride	28	11
Levetiracetam	Levetiracetam	28	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	27	suppressed
Pramipexole Dihydrochloride	Pramipexole Di-Hcl	27	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	26	suppressed
Hydralazine Hcl	Hydralazine Hcl	26	suppressed
Montelukast Sodium	Montelukast Sodium	26	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	26	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	25	suppressed
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	25	suppressed
Ventolin Hfa	Albuterol Sulfate	25	suppressed
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	24	suppressed
Carbidopa-Levodopa Er	Carbidopa/Levodopa	23	suppressed
Ipratropium Bromide	Ipratropium Bromide	23	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	23	suppressed
Breo Ellipta	Fluticasone/Vilanterol	22	suppressed
Bupropion Xl	Bupropion Hcl	22	suppressed
Mounjaro	Tirzepatide	22	suppressed
Nitroglycerin	Nitroglycerin	22	18
Tresiba Flextouch U-100	Insulin Degludec	22	suppressed
Basaglar Kwikpen U-100	Insulin Glargine,hum.Rec.Anlog	21	suppressed
Doxycycline Hyclate	Doxycycline Hyclate	21	15
Pravastatin Sodium	Pravastatin Sodium	21	suppressed
Terbinafine Hcl	Terbinafine Hcl	21	suppressed
Digoxin	Digoxin	20	suppressed
Ezetimibe	Ezetimibe	19	suppressed
Incruse Ellipta	Umeclidinium Bromide	19	suppressed
Ketoconazole	Ketoconazole	19	suppressed
Novolin 70-30 Flexpen	Insulin Nph Hum/Reg Insulin Hm	18	suppressed
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	18	suppressed
Benazepril Hcl	Benazepril Hcl	17	suppressed
Breyna	Budesonide/Formoterol Fumarate	17	suppressed
Cephalexin	Cephalexin	17	13
Enalapril Maleate	Enalapril Maleate	17	suppressed
Fenofibrate	Fenofibrate Nanocrystallized	17	suppressed
Fluticasone Propionate Hfa	Fluticasone Propionate	17	suppressed
Prazosin Hcl	Prazosin Hcl	17	suppressed
Pregabalin	Pregabalin	17	suppressed
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	16	suppressed
Januvia	Sitagliptin Phosphate	16	suppressed
Mirtazapine	Mirtazapine	16	suppressed
Sumatriptan Succinate	Sumatriptan Succinate	16	suppressed
Promethazine Hcl	Promethazine Hcl	15	suppressed
Zolpidem Tartrate	Zolpidem Tartrate	15	suppressed
Chlorthalidone	Chlorthalidone	14	suppressed
Entresto	Sacubitril/Valsartan	14	suppressed
Myrbetriq	Mirabegron	14	suppressed
Azithromycin	Azithromycin	13	suppressed
Mupirocin	Mupirocin	13	suppressed
Symbicort	Budesonide/Formoterol Fumarate	13	suppressed
Metolazone	Metolazone	12	suppressed
Novolog Flexpen	Insulin Aspart	12	suppressed
Baclofen	Baclofen	11	suppressed
Butalbital-Acetaminophen-Caffe	Butalb/Acetaminophen/Caffeine	11	suppressed
Cartia Xt	Diltiazem Hcl	11	suppressed
Morphine Sulfate Er	Morphine Sulfate	11	suppressed
Synthroid	Levothyroxine Sodium	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error